Dr. Sarah Chen
June 17, 2026
The obesity pharmacotherapy landscape has evolved rapidly since the introduction of GLP-1 receptor agonists. While agents like semaglutide (Wegovy, Ozempic) have achieved clinical acceptance and substantial weight loss, researchers recognized a fundamental limitation: GLP-1 monotherapy alone does not fully replicate the satiety signaling of the endocrine pancreas. This gap led Novo Nordisk to develop cagrilintide, a synthetic long-acting amylin analog designed to work synergistically with GLP-1 agonism.
Understanding what is a GLP-1 receptor agonist remains essential context. GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by intestinal L-cells in response to nutrient intake; it stimulates insulin secretion, slows gastric emptying, and signals satiety via central nervous system pathways. However, amylin—a pancreatic peptide co-secreted with insulin—operates through distinct receptor mechanisms to enhance satiety and regulate glucose homeostasis independently of GLP-1. By combining both pathways, cagrilintide-semaglutide (CagriSema) targets complementary neuroendocrine circuits, a strategy fundamentally different from the triple-agonist approach employed by retatrutide.
Cagrilintide (developmental code NN9838, also referred to as AM833) is a once-weekly subcutaneous amylin and calcitonin receptor agonist engineered for long-acting depot formulation. Unlike GLP-1 agonists that primarily suppress appetite through central GLP-1 receptor signaling and delayed gastric emptying, cagrilintide activates amylin receptors distributed across the hypothalamus, brainstem, and peripheral tissues.
Amylin receptor activation produces three distinct metabolic effects:
This multi-mechanism profile explains why cagrilintide in combination with semaglutide produces weight loss exceeding either agent alone—the two peptides converge on overlapping satiety circuits through distinct molecular pathways.
#### REDEFINE 1: Obesity Without Type 2 Diabetes
The pivotal REDEFINE 1 trial enrolled 3,417 adults with obesity or overweight plus at least one weight-related comorbidity, excluding those with type 2 diabetes. Participants received either CagriSema (cagrilintide 2.4 mg + semaglutide 2.4 mg once-weekly), or placebo, for 68 weeks alongside lifestyle intervention.
Primary efficacy findings:
These results represent a meaningful advance over semaglutide monotherapy. According to a 2026 meta-analysis pooling three randomized controlled trials (n=3,545), CagriSema produced significantly greater percentage weight loss than semaglutide monotherapy: mean difference −7.47% (95% CI not fully specified in public summaries). In absolute terms, CagriSema achieved approximately 7.60 kg greater weight loss than semaglutide alone [peptidehackerlab.com](https://peptidehackerlab.com/compounds/cagrilinitide-evidence/).
#### REIMAGINE 1: Type 2 Diabetes Inadequately Controlled on Lifestyle
The REIMAGINE 1 trial represents the first randomized evaluation of a combined amylin/GLP-1 agonist for type 2 diabetes not optimally managed with diet and exercise alone. After 40 weeks of treatment, both CagriSema 2.4 mg each and CagriSema 1.0 mg each were superior to placebo for the primary endpoint of HbA1c reduction, with participants achieving recommended HbA1c targets at significantly higher rates than placebo controls [sciencedirect.com](https://www.sciencedirect.com/science/article/abs/pii/S2213858726001269).
However, efficacy in the diabetic population was more modest than in non-diabetic obesity: REDEFINE 2 (CagriSema in type 2 diabetes with prior oral agents) showed 15.7% mean weight loss at 68 weeks, compared to 3.1% with placebo. This 12.6-percentage-point treatment difference, while clinically significant, underscores that weight loss is more challenging to achieve in patients with established diabetes and metabolic dysfunction.
The central question for researchers and clinicians is how cagrilintide's dual-agonist strategy compares to retatrutide's triple-agonist approach. Current evidence provides a clear answer: retatrutide produces greater weight loss than CagriSema, but CagriSema is likely to reach market sooner.
#### Retatrutide: The Triple-Agonist Benchmark
Retatrutide (LY3437943), developed by Eli Lilly, is a first-in-class GIP/GLP-1/glucagon receptor agonist. In Phase 3 TRIUMPH-4, retatrutide 12 mg achieved 28.7% mean weight loss at 68 weeks in adults with obesity, confirming Phase 2 results (24.2% at 48 weeks). This represents the highest weight loss recorded with any single anti-obesity agent in clinical trials.
Retatrutide's glucagon component increases energy expenditure—a mechanism distinct from appetite suppression alone. By activating GIP and glucagon receptors in addition to GLP-1 pathways, retatrutide stimulates brown adipose tissue thermogenesis and increases resting metabolic rate, providing a dual mechanism: reduced intake *and* increased expenditure.
#### The Efficacy Gap
CagriSema achieved 20.4% weight loss in REDEFINE 1 (obesity) and 15.7% in REDEFINE 2 (type 2 diabetes). Retatrutide achieved 28.7% in TRIUMPH-4 obesity trials. The efficacy gap—approximately 8.3 percentage points in the obesity population—is substantial and clinically meaningful.
Critically, this gap persists across indications. In type 2 diabetes populations, retatrutide's advantage appears consistent with its obesity data, suggesting the triple-agonist mechanism provides benefit independent of disease state [biomednexus.com](https://biomednexus.com/retatrutide-vs-cagrisema-why-2026-is-the-year-of-the-triple-agonist/).
Meta-analytic data from Ahmed et al. (2026) pooling three randomized controlled trials (n=3,545) comparing CagriSema and cagrilintide monotherapy against semaglutide identified important safety signals:
The LDL-cholesterol signal warrants monitoring in longer-term cardiovascular outcome trials, particularly given the population's baseline cardiovascular risk. Gastrointestinal tolerability appears comparable or superior to semaglutide monotherapy in some analyses, suggesting cagrilintide's amylin pathway may produce less nausea/vomiting than GLP-1 monotherapy at equivalent weight loss.
Novo Nordisk filed an NDA with the FDA for CagriSema in late 2025, positioning the compound for earlier market entry than retatrutide. Seven Phase 3 trials of retatrutide are expected to report throughout 2026, covering obesity, type 2 diabetes, sleep apnea, chronic low back pain, liver disease, and cardiovascular outcomes. If these trials confirm TRIUMPH-4 efficacy, retatrutide will establish a differentiated product that CagriSema cannot match on weight loss efficacy alone.
However, CagriSema's earlier market entry, established semaglutide safety database, and fixed-dose convenience may confer advantages in specific patient populations—particularly those with contraindications to glucagon receptor activation or those seeking a GLP-1/amylin combination already validated in clinical practice.
Cagrilintide represents a scientifically elegant proof-of-concept: targeting complementary neuroendocrine pathways produces additive weight loss beyond either agent alone. The amylin receptor system, long neglected in obesity pharmacotherapy, provides a distinct satiety signal that converges on central appetite circuits via different molecular mechanisms than GLP-1.
Yet the efficacy data also establish clear boundaries: the triple-agonist mechanism (GIP/GLP-1/glucagon) produces greater weight loss than dual-agonist approaches (amylin/GLP-1). Whether this 8-percentage-point difference translates to superior cardiovascular outcomes, improved metabolic disease remission, or better long-term weight maintenance remains unknown and will require dedicated outcome trials.
For researchers tracking the obesity-drug competitive landscape, 2026 will be decisive. CagriSema's market entry will provide real-world efficacy and safety data across diverse populations. Simultaneously, retatrutide's Phase 3 readouts will clarify whether triple-agonist superiority extends to type 2 diabetes, cardiovascular disease, and metabolic complications. The data will determine whether obesity treatment evolves toward dual-mechanism combinations or triple-agonist monotherapy—or whether both approaches find distinct clinical niches.
Cagrilintide (CagriSema) achieves 20.4% weight loss through complementary amylin and GLP-1 receptor agonism, representing a meaningful advance over semaglutide monotherapy. However, retatrutide's triple-agonist mechanism produces 28.7% weight loss, establishing a substantial efficacy advantage that persists across obesity and type 2 diabetes indications. The choice between these agents will depend on regulatory approval timelines, real-world tolerability, long-term cardiovascular outcome data, and individual patient factors—not efficacy alone.